WHO Backs Experimental Ebola Vaccine as Singapore Lab Leads Race Against Bundibugyo Outbreak

As a rare Ebola strain tears through central Africa with no approved vaccine, a Singapore lab has been picked to develop what global health experts call the “most promising” shot to stop it.

Story Snapshot

World Health Organization experts have named a single-dose rVSV Bundibugyo vaccine as the top candidate to fight the current Ebola Bundibugyo outbreak.
Singapore-based Hilleman Laboratories will now develop and produce doses of this vaccine for human trials, backed by international funding.
There is still no licensed vaccine or specific treatment for Bundibugyo virus disease, despite thousands of cases and hundreds of deaths.
The fast-track push for this “most promising” vaccine raises big questions about speed, safety, and who controls high-risk research in a global emergency.

WHO backs a single-dose Bundibugyo Ebola vaccine

World Health Organization (WHO) experts met in late May and reviewed all the experimental vaccines for Ebola disease caused by Bundibugyo virus. After looking at the data, they said the most promising option is a single-dose vaccine that uses recombinant vesicular stomatitis virus, called rVSV Bundibugyo. This candidate comes from the International AIDS Vaccine Initiative and is built on the same basic platform as Merck’s approved Ervebo vaccine for the Zaire Ebola strain, which showed strong protection in trials.

The WHO experts said this Bundibugyo shot could be ready to test in people in about seven to nine months. That is a tight timeline for any vaccine, especially one based on a live, replicating virus platform. The rVSV system has shown it can give powerful immune responses with a single dose in earlier Ebola work, including proof-of-concept animal studies for Bundibugyo, but real-world human data for this specific strain do not yet exist. For now, WHO’s “most promising” label rests on lab and animal results, not completed human trials.

Singapore’s Hilleman Laboratories chosen to build and scale the shot

To move from theory to practice, the Coalition for Epidemic Preparedness Innovations (CEPI) has turned to Hilleman Laboratories, based in Singapore. CEPI announced funding of up to $8.5 million so Hilleman can develop and manufacture clinical trial supplies of the rVSV Bundibugyo vaccine at its production facility. Hilleman will start from the candidate material generated by the International AIDS Vaccine Initiative and refine the manufacturing process, with the goal of making doses ready for human testing as the outbreak continues.

Hilleman Laboratories is a joint venture between the drug company MSD and the Wellcome charitable foundation. This mix of private pharma and philanthropy reflects a wider pattern many Americans now worry about: life-and-death public health tools, like vaccines, often depend on global partnerships led by large corporations and elite organizations, rather than clear, accountable national systems. The partnership will also build know-how in the rVSV platform, which Hilleman and others may later use to make more vaccines against other dangerous viruses.

No approved Bundibugyo vaccine as outbreak toll climbs

While this new vaccine work ramps up, people in the Democratic Republic of the Congo and Uganda are facing a fast-moving outbreak with no licensed Bundibugyo-specific vaccine or treatment. WHO reports hundreds of confirmed cases and many deaths, and regional agencies now call it a public health emergency that threatens continental security. Doctors Without Borders and others stress that care still depends on basic steps: rapid case finding, isolation, contact tracing, safe burials, and community trust.

For Bundibugyo virus, earlier studies found a death rate of around 40 percent among confirmed cases, which is lower than some past Ebola strains but still severe. Existing approved Ebola vaccines, like Ervebo, target the Zaire strain and are not approved for Bundibugyo; cross-protection appears incomplete and has not been proven in people for this outbreak. Global health agencies, including CEPI and Africa’s disease control body, have made it clear that new vaccines tailored to Bundibugyo are an urgent priority, reinforcing the push behind the rVSV Bundibugyo project.

Rushing “the most promising” vaccine raises hard questions

The decision to fast-track a single “most promising” vaccine in under a year highlights a tension many citizens know well: the world needs quick action, but rushed science can have hidden costs. The rVSV platform has shown strong promise in past Ebola work, and WHO’s experts weighed options before picking this candidate. Another vaccine, called ChAdOx1 Bundibugyo from Oxford and the Serum Institute of India, could be ready for trials in just two to three months, showing there is more than one path under study.

🇨🇩 BREAKING: DRC Ebola outbreak hits 3,075 cases, 1,354 deaths.

⚡ Fastest-growing outbreak in history
⚡ Rare Bundibugyo strain — no cure
⚡ WHO declares global health emergency

👇 Should the world respond faster?#DRC #Ebola #GlobalHealth #WHO #BreakingNews pic.twitter.com/oW41S1fvQW

— Septentria News (@SeptentriaNews) July 27, 2026

People on both the left and the right often fear that unelected global health bodies and corporate labs make major choices far from public view. Here, WHO, CEPI, and large research groups are deciding which experimental shots move forward, how fast, and with what safeguards. At the same time, local health systems in Congo and Uganda struggle with basics like clean water, protective gear, and clear messaging, as reports of weak preparedness and limited resources continue. This gap between high-tech vaccine labs and fragile front-line care deepens concern that the system serves elites first and ordinary people last.

Why this matters beyond Africa’s borders

For Americans watching from home, experts say the direct risk from this Bundibugyo outbreak is still low, and no related cases have been confirmed in the United States. Yet the story carries wider meaning. A rare, deadly virus is spreading in a region marked by conflict and weak infrastructure, while global institutions rush to back an advanced, unlicensed vaccine built by a lab half a world away. The choices made now will shape how future epidemics are handled, who controls vaccines, and how much ordinary citizens can trust the process.

Many voters already feel the federal government cannot be counted on to protect them when crises hit, whether those crises are economic or biological. Seeing major outbreak decisions driven by distant agencies and global partnerships may only strengthen that skepticism. At the same time, the lack of any approved Bundibugyo vaccine or treatment shows what happens when the world waits too long to invest in serious preparedness. The Singapore-led effort could save lives if the science holds up, but it also reminds us that accountability, transparency, and early action are not luxuries; they are the pillars of real security in a dangerous world.